Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A4 study of solanezumab in preclinical Alzheimer's disease
ACTRN12615000500550Phase 3Recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Solanezumab with Placebo (2 arms). Primary endpoint: Change in Cognitive Function Index. Started Dec 2014; status: recruiting.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12615000500550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000500550.